Stevens Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but life-threatening cutaneous drug reactions with multi organ system involvement. It is most often caused by medications in the form of a severe allergic reaction resulting in burn-like lesions over the entire body. There is also mucous membrane and other organ system involvement which affects the dermatologic, ocular, oral and gastrointestinal, respiratory, gynaecologic, urologic, otolaryngologic, and hepatorenal systems. There is also significant mental health disease associated with SJS/TEN. Psychiatric medications are often the cause of SJS/TEN and once a patient develops SJS/TEN, they can no longer be on their first line medication, exacerbating underlying mental health disease.
Unfortunately, there is no cure for SJS/TEN and no adequate prevention mechanisms. The acute phase of the disease is largely supportive. Those who survive can face severe and debilitating symptoms involving the skin, eyes, lungs, genitourinary system, and gastrointestinal tract. There are a few groups internationally working on identifying genetic risk factors that may predispose patients to developing SJS/TEN. While there is significant and growing international interest in SJS/TEN and there are several international experts in this field, there are no collections in the literature on this disease from experts in every organ system. We recently had an international SJSTEN symposium in August 2021 where leaders in the field delivered updates on the status and management of this disease.
In this vein, this Research Topic aims to assemble articles authored by experts in the field using evidence-based and practice-based experience to provide readers with an update on current disease diagnosis, management, prognosis and future directions. This Topic would also include updates from the recent SJSTEN international symposium and a tribute to the late Professor Jean-Claude Roujeau who passed earlier this year and pioneered much of what is known about SJS/TEN.
The scope of this Research Topic includes updates in the form of reviews and mini-reviews from international experts on the clinical disease of SJS/TEN. Themes of interest include but are not limited to:
• The cutaneous and multi-organ disease in SJS/TEN including that of the ocular, oral and gastrointestinal, respiratory, gynaecologic, urologic, otolaryngologic, and hepatorenal systems
• Immunology of SJS/TEN
• Vulnerable populations in SJS/TEN including children, minorities, and those with HIV
• Genetic risk factors for developing the disease
• Public health impacts.
Stevens Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but life-threatening cutaneous drug reactions with multi organ system involvement. It is most often caused by medications in the form of a severe allergic reaction resulting in burn-like lesions over the entire body. There is also mucous membrane and other organ system involvement which affects the dermatologic, ocular, oral and gastrointestinal, respiratory, gynaecologic, urologic, otolaryngologic, and hepatorenal systems. There is also significant mental health disease associated with SJS/TEN. Psychiatric medications are often the cause of SJS/TEN and once a patient develops SJS/TEN, they can no longer be on their first line medication, exacerbating underlying mental health disease.
Unfortunately, there is no cure for SJS/TEN and no adequate prevention mechanisms. The acute phase of the disease is largely supportive. Those who survive can face severe and debilitating symptoms involving the skin, eyes, lungs, genitourinary system, and gastrointestinal tract. There are a few groups internationally working on identifying genetic risk factors that may predispose patients to developing SJS/TEN. While there is significant and growing international interest in SJS/TEN and there are several international experts in this field, there are no collections in the literature on this disease from experts in every organ system. We recently had an international SJSTEN symposium in August 2021 where leaders in the field delivered updates on the status and management of this disease.
In this vein, this Research Topic aims to assemble articles authored by experts in the field using evidence-based and practice-based experience to provide readers with an update on current disease diagnosis, management, prognosis and future directions. This Topic would also include updates from the recent SJSTEN international symposium and a tribute to the late Professor Jean-Claude Roujeau who passed earlier this year and pioneered much of what is known about SJS/TEN.
The scope of this Research Topic includes updates in the form of reviews and mini-reviews from international experts on the clinical disease of SJS/TEN. Themes of interest include but are not limited to:
• The cutaneous and multi-organ disease in SJS/TEN including that of the ocular, oral and gastrointestinal, respiratory, gynaecologic, urologic, otolaryngologic, and hepatorenal systems
• Immunology of SJS/TEN
• Vulnerable populations in SJS/TEN including children, minorities, and those with HIV
• Genetic risk factors for developing the disease
• Public health impacts.